

**PATHWAY BASED FACTOR ANALYSIS OF GENE EXPRESSION
DATA PRODUCES HIGHLY HERITABLE PHENOTYPES THAT
ASSOCIATE WITH AGE**

ANDREW BROWN^{*,†,1}, ZHIHAO DING^{*,1}, ANA VIÑUELA[§], DAN GLASS[§],
LEOPOLD PARTS^{*}, TIM SPECTOR[§], JOHN WINN^{**}, RICHARD DURBIN^{*,2}

** Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1HH, UK*

*† NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental
Health and Addiction, Oslo University Hospital, Oslo, Norway*

*§ Department of Twin Research and Genetic Epidemiology, King's College London,
St Thomas' Campus, Westminster Bridge Road, London SE1 7EH, UK*

*** Microsoft Research, 21 Station Road, Cambridge CB1 2FB, UK*

¹These authors contributed equally to this work.

²Corresponding author. Email: rd@sanger.ac.uk

ABSTRACT. Statistical factor analysis methods have previously been used to remove noise components from high dimensional data prior to genetic association mapping, and in a guided fashion to summarise biologically relevant sources of variation. Here we show how the derived factors summarising pathway expression can be used to analyse the relationships between expression, heritability and ageing. We used skin gene expression data from 647 twins from the MuTHER Consortium and applied factor analysis to concisely summarise patterns of gene expression, both to remove broad confounding influences and to produce concise pathway-level phenotypes. We derived 930 “pathway phenotypes” which summarised patterns of variation across 186 KEGG pathways (five phenotypes per pathway). We identified 69 significant associations of age with phenotype from 57 distinct KEGG pathways at a stringent Bonferroni threshold ($P < 5.38 \times 10^{-5}$). These phenotypes are more heritable ($h^2 = 0.32$) than gene expression levels. On average, expression levels of 16% of genes within these pathways are associated with age. Several significant pathways relate to metabolising sugars and fatty acids, others with insulin signalling. We have demonstrated that factor analysis methods combined with biological knowledge can produce more reliable phenotypes with less stochastic noise than the individual gene expression levels, which increases our power to discover biologically relevant associations. These phenotypes could also be applied to discover associations with other environmental factors.

Keywords: Ageing; Factor analysis; Gene expression; Heritability; Linear Mixed Models

1. INTRODUCTION

Ageing is a multifactorial process, reflecting how the physical state of an organism accumulates changes. Amongst these, we observe changes in gene expression. Microarrays and more recent RNA-seq technologies allow the simultaneous quantification of cell population average mRNA abundance for thousands of genes. In the case of ageing, consistent patterns of age-related changes in gene expression have been observed across several tissues and species [Lu et al., 2004], such as over-expression of inflammation and immune-response genes and under-expression of genes involved in energy metabolism in older samples [de Magalhaes et al., 2009]. Given this commonality of function amongst

genes which show age related changes in expression, we decided to investigate ageing dependent gene expression in the context of biological knowledge on the function of genes, as provided by pathway annotations.

Array expression experiments generate high dimensional structured data sets, in which there are correlated patterns across large numbers of genes. Some of these are due to known technical or biological effects such as batch effects and cell growth stage, which when not the focus of the analysis can be removed by fitting them as covariates. However, even after this, there is typically substantial structural correlation. In previous studies, these can be represented by linear components of expression measurements, or factors, that can be inferred using methods such as principal components analysis (PCA) or factor analysis [Leek and Storey, 2007, Parts et al., 2011]. When the aim is to discover local effects, such as *cis* genetic regulation, the resulting factors can be treated as nuisance variables and removed from further analysis. This has been seen to increase power in analysis [Pickrell et al., 2010]. Conversely, if the aim is to differentiate between a case and control condition using expression, then factors viewed as global phenotypes could be more effective classifiers than local phenotypes [Hastie et al., 2000].

Recently we applied factor analysis methods in a two stage procedure to generate phenotypes representing expressions of groups of genes [Stegle et al., 2012]. After regressing out global factors, as in Parts et al. [2011], expression levels for groups of functionally related genes, as defined by annotations from pathway databases, were treated as new expression datasets and the same factor analysis methods were used to construct pathway factors. The factors constructed on pathway sets of genes were taken as concise summaries of common expression variation across each pathway. We test these factor values below as phenotypes, and so refer to them as phenotype factors or, in some cases, just phenotypes.

Here, we apply this method to gene expression data from abdominal skin tissues from 647 samples. Unlike previous studies which have concentrated on genetic variants which regulate multiple genes within a pathway [Stegle et al., 2012], we focus here on discovering associations between gene expression and age. We obtain our pathway gene sets from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [Kanehisa et al., 2004]. Subsequently, by looking for associations between these new pathway phenotypes and age, we discover groups of functionally related genes with a common response to ageing which can be used as biomarkers describing molecular changes with age.

With data from a twin cohort containing both monozygotic and dizygotic twins, we can estimate proportions of variance explained by age, genetic variation, common environmental variation, and unique environmental variation (noise). Stochasticity in gene expression, which will form part of the unique environment component, is believed to play a role in the ageing process [Bahar et al., 2006]. By investigating sources of variation within the pathway phenotypes, we find that they are more robust than the expression of individual genes, with less unique environment variation. This explains some of our success at discovering associations with age.

2. METHODS

2.1. Expression profiling. The data analysed here are part of the MuTHER project (Multiple Tissue Human Expression Resource - <http://www.muther.ac.uk/>, [Nica et al., 2011]) and were downloaded from the ArrayExpress archive, accession no. E-TABM-1140. In summary, the study included 856 Caucasian female individuals (336 monozygotic (MZ) and 520 dizygotic (DZ) twins) recruited from the TwinsUK Adult twin registry [Moayyeri et al., 2012]. The age at sampling ranged from 39 to 85 years with a mean age of 59 years. Punch biopsies (8mm) were taken from relatively photo-protected infra-umbilical skin. Subcutaneous adipose tissue was dissected from each biopsy and the remaining skin tissue was weighed and stored in liquid nitrogen. Expression profiling of this skin tissue was performed using Illumina Human HT-12 V3 BeadChips where 200ng of total RNA was processed according to the protocol supplied by Illumina. All samples were randomised prior to array hybridisation and the technical replicates were always hybridised on different beadchips. Raw data were imported to the Illumina Beadstudio software and probes with fewer than three beads present were excluded. Log₂-transformed expression signals were then normalised separately per tissue with quantile normalisation of the replicates of each individual followed by quantile normalisation across all individuals as previously described [Grundberg et al., 2012]. Post-QC expression profiles were subsequently obtained for 647 individuals. The Illumina probe annotations were cross-checked by mapping the probe sequence to the NCBI Build 36 genome with MAQ [Li et al., 2008]. Only uniquely mapping probes with no mismatches and either an Ensembl or RefSeq ID were kept for analysis. Probes mapping to genes of uncertain function (LOC symbols) and those encompassing a common SNP (1000G release June 2010) were further excluded, leaving 23,555 probes used in the analysis.

Box 1: Modelling

We model phenotype y_i of individual i (age A_i) as follows:

$$\begin{aligned} \text{(FULL)} \quad y_i &= \mu + \alpha A_i + \beta_i + \gamma_i + \epsilon_i, \beta_i \sim N(0, \sigma_{FAM}^2) \\ &\gamma_i \sim N(0, \sigma_{MZ}^2) \\ &\epsilon_i \sim N(0, \sigma^2) \end{aligned}$$

$$\begin{aligned} \text{(NULL)} \quad y_i &= \mu + \beta_i + \gamma_i + \epsilon_i, \beta_i \sim N(0, \sigma_{FAM}^2) \\ &\gamma_i \sim N(0, \sigma_{MZ}^2) \\ &\epsilon_i \sim N(0, \sigma^2) \end{aligned}$$

To correctly model the twin structure we enforce that $\beta_i = \beta_j$ when i and j are twins, and $\gamma_i = \gamma_j$ when i and j are monozygotic twins (capturing the increased genetic correlation of monozygotic twins).

From the full model we can define heritability (h^2), proportion of environmental variance explained by age (ρ_a) and the proportion of variance explained by the unique environment (ρ_e) as:

$$\begin{aligned} h^2 &= \frac{2\sigma_{MZ}^2}{\sigma_{FAM}^2 + \sigma_{MZ}^2 + \sigma^2 + \alpha_i^2 \text{var}(A_i)} \\ \rho_a &= \frac{\alpha_i^2 \text{var}(A_i)}{\sigma_{FAM}^2 - \sigma_{MZ}^2 + \sigma^2 + \alpha_i^2 \text{var}(A_i)} \\ \rho_e &= \frac{\sigma^2}{\sigma_{FAM}^2 + \sigma_{MZ}^2 + \sigma^2 + \alpha_i^2 \text{var}(A_i)} \end{aligned}$$

2.2. Gene expression pathway factors. In a two step approach, factor analysis methods were first used to discover patterns of common variation across the entire dataset. The software package PEER [Parts et al., 2011] was applied using the default settings and using technical measurements (experimental batch, RNA quality and concentration) as covariates to create 5 global factors, which in total explained 35.7% of the variation in the dataset. For each individual, a factor is a weighted sum of all the gene expression measurements of that individual. The weights are chosen so that the factors iteratively

explain the maximum amount of variation in the dataset subject to certain prior assumptions; these factors produce concise summaries of consistent patterns of expression for large numbers of genes.

We then used KEGG pathway annotation (186 pathways) as prior information to group genes into pathways. This allows inference of PEER factors for each pathway that we refer to as phenotype factors, in contrast to the global factors previously described. As before, these factors are weighted sums of gene expression measurements, but in this case only of genes within the pathway. Since global factors have been removed from the dataset prior to calculation of phenotype factors, these factors are unlikely to capture global effects on gene expression, but instead pathway specific patterns of expression. If a large enough module of genes within the pathway is co-expressed then one factor will capture the same pattern of co-expression across individuals. Equally, groups of genes could show opposite patterns of expression; this antagonistic gene expression can also be reflected as a factor value which correlates across individuals with one set of genes and is anti-correlated with the other set of genes. Individual genes can contribute positively or negatively to the weighted sum (indicated by the sign of the corresponding weight), meaning that a positive correlation between age and phenotype factor can be induced by negative correlations with individual genes.

We grouped the expression data set into 186 pathway subsets. For each pathway we created five pathway phenotypes using PEER with the default settings. We consider the learnt pathway factor values across individuals as five new phenotypes which can be investigated for associations with age. An alternative strategy would be to choose different numbers of factors based on the cumulative amount of variance explained. For the sake of simplicity and as a proof of principle, in this analysis we chose to use five factors as they explained a substantial amount of the variance in expression (17.5%) without too large a multiple testing burden. The sixth factor on average would have explained 2.2% more of the variance.

2.3. Pathway factor and phenotype association. Association tests were performed using the linear mixed models defined in Box 1: i) between each pathway factor and chronological age, and ii) between single genes and chronological age. These models have been implemented by the lme4 package [Bates et al., 2014] in R [R Core Team, 2013]. For each phenotype a likelihood ratio test of the full model, which includes the age term, and the null model (without modelling age) was used to assess evidence for an age effect. P

values produced by this analysis were assessed for significance allowing for multiple testing using a Bonferroni adjusted threshold. Permuted datasets were created which maintained the twin structure by permuting singletons, dizygotic and monozygotic twins separately and ensuring that twin pairs were kept together.

Significant associations between phenotype factors and age were further investigated to trace the particular genes within the pathway driving the signal. We report genes with a Bonferroni significant P value which accounts for the number of genes within the pathway that was tested.

2.4. Heritability analysis. To compute heritability, the proportion of environmental variance explained by age, and the proportion of variance explained by unique environment, we fitted the full model from Box 1. Then the genetic component to variation was estimated as twice the additional correlation of MZ twins relative to DZ twins. The environmental component to the phenotype was the sum of the contribution from the fixed age effect, the random noise term, and the shared environmental component, again estimated from the difference between MZ and DZ. Estimates of these proportions are constrained to lie between 0 and 1 inclusive.

2.5. Single-gene based pathway enrichment analysis. We compared the significant pathways found by our factor analysis methods to those found by looking for enrichment of single gene associations with age. Firstly we tested each gene for association with age using the methods described in Box 1 and produced a list of Bonferroni significant genes $P < 0.05$ (this list contained 682 differentially expressed genes). For each pathway, we applied a Fisher's exact test to infer whether the proportion of significantly associated genes within the pathway was greater than would be expected by chance. We also investigated whether using an FDR cut-off for significant age associations would produce more significant pathways or power would be diluted by including too many false positives. When re-running the analysis using a less stringent threshold (3,487 genes were associated with age with $FDR < 0.05$) we found fewer significant pathways, and results correlated less well with the results of the factor based analysis (Spearman correlation of 0.36 ($P = 5.1 \times 10^{-7}$) compared to 0.49 for Bonferroni, $P = 2.1 \times 10^{-12}$). A complete list of all significant single gene age associations ($FDR < 0.05$, 3,487 genes), with estimate of effect size and direction, can be found in Supplementary File 1.

3. RESULTS

The first stage of the analysis was to remove the effect of both known and unknown nuisance variables from the gene expression data. Using PEER software, we estimated five global factors which explained 35.7 % of the variation in the complete gene expression data. As the aim of this analysis was to find pathway specific responses to ageing, we treated these global factors as nuisance covariates and regressed these out of the data, together with batch and RNA quality which are known experimental confounders. Data were then divided into subsets of genes within 186 KEGG pathways that contained more than 10 genes with probes in our dataset. For each pathway, five factors were estimated using PEER as described above, which explained on average 17.5% of the residual variation of all genes within this pathway after removing the global factors. For the 186 KEGG pathways, this produced 930 phenotypes which were tested for association with age (see Methods for details). In total, 69 significant associations ($P < 5.38 \times 10^{-5}$, the Bonferroni adjusted threshold) from 57 distinct pathways were identified. The most significant 20 pathways are listed in Table 1, and a list of all 57 significant pathways can be found in the Supplementary materials (Supplementary Table S1).

We also explored an alternative method for finding pathway related to ageing, looking for enrichment in the number of significantly associated genes falling into a particular pathway, analogous to the method used in the DAVID methodology [Huang et al., 2009]. This discovered a total of 7 significant pathways (Supplementary Table S2). Thus, applying factor analysis methods to discover significantly associated pathways uncovered eight times as many hits. All pathways discovered by single gene enrichment methods were also discovered using factor analysis. There is strong concordance between P values discovered by the two methods (Spearman correlation = 0.49, $P = 2.1 \times 10^{-12}$). Figure 1 shows a Q-Q plot of p values for both methods against the theoretical p values under the complete null hypothesis. We see enrichment of significant P values for both methods, but this is not present when analysing the permuted data with factor analysis methods (green dots). This suggests that age plays a widespread role in the expression of these pathways.

To investigate which genes drove the significant pathway associations, we examined how many genes within a significant pathway showed significant age associations (Table 1 and Supplementary Table S1). On average 16% of genes within the pathways have $P < 0.05$ after adjusting for the number of genes in the pathway, with a minimum of 1 gene and

maximum of 24. The proportion is similar between pathways of different sizes, in contrary to the traditional pathway enrichment analysis, where there is bias towards large pathways.

Different KEGG pathways can contain overlapping sets of genes, as they can describe related biological function. Because of this, our significant associations with age for different pathways could be related due to a common underlying effect on a given set of genes. To explore whether the observed age-associations are unique to their pathway, or common to multiple pathways, we calculated the Spearman correlation between those phenotypes. There are 24 pathway phenotypes with a correlation greater than 0.8 with at least one other phenotype (Supplementary Table S3). These phenotypes frequently relate to metabolism, and form a highly connected set (Supplementary Figure S1). We infer from this that there could be a common effect of age acting on these phenotype factors. However, these form only a minority of the phenotype factors with significant signal.

We next explored how different sources of variation in the different phenotypes analysed here affect our ability to discover age associations. We calculated the heritabilities, the proportion of environmental variance explained by age, and the proportion of variance explained by the unique environment (Box 1) for i) KEGG pathways, ii) global factors (which we have treated as nuisance covariates) and iii) for individual genes (Figure 2, global factor histograms are not shown as there are too few phenotypes). The relative differences in sources of variation between global and pathway factors, and individual genes are shown in Figure 3. We see that as we move away from local phenotypes (individual genes) to pathway phenotypes and then to global phenotypes, the proportion of variation explained by unique environment decreases. This is because that there is a stochastic component to each single gene's expression: by taking a weighted average of a number of genes, we average away this component. If all else were to remain constant, this reduction in stochastic noise would simultaneously increase heritability (as the total variance decreases), and boost the ability to discover associations with biological meaning, such as age. We see in the first panel of Figure 3 that the relative contribution of unique environment to pathway phenotypes is smaller than the contribution to genes. This also partly explains the results shown in the second and third panels: a greater proportion of variance is explained by age and genetic factors (heritability) for pathway factors than individual gene measurements.

When considering global factors, as expected the unique environment is greatly reduced. However, there is not a strong influence of ageing and heritability in this case is still

moderate. This is likely because age and genetics do not act in a consistent way across large sets of genes. Leek and Storey [2007] argued that global factors can capture experimental noise and batch effects. This is consistent with our findings. Heritabilities and proportion of variance explained by age for each pathway are reported in Supplementary Table S4.

We further looked for novel genetic associations with these pathway phenotypes, not seen as single gene expression associations. However, this was unsuccessful despite the increased heritability in pathway factors. This is likely due to the genetic architecture of gene regulation. Genes are regulated both in *cis*, where a nearby variant effects the expression of a single gene, and in *trans*, where a long range regulatory effect can hit multiple genes [Grundberg et al., 2012]. The genetics of pathway phenotypes is a combination of *cis* effects on individual genes and *trans* effects, potentially affecting multiple genes in the pathway. However, *trans* variants typically have much smaller effect size: the increase in the reliability of pathway phenotypes is insufficient to compensate for the lower power to discover *trans* effects. Thus, the only associations discovered were when single genes loaded heavily enough on a pathway to indirectly reflect a *cis* association that could be detected in a single gene test.

4. DISCUSSION

We have seen that both the heritability and the proportion of environmental variance explained by age is greater for pathway phenotypes than for individual genes. Consistent with this, we found a greater proportion of associations for the pathway phenotypes than using single gene tests using this same dataset [Glass et al., 2013] (23% compared to 7% of phenotypes are significantly associated with age when using the same 0.05 FDR threshold adopted in that paper). This can be explained by our findings on the influence of unique environment on pathway phenotypes relative to single genes.

Stochasticity in gene expression, which contributes to the unique environment component that we measure, has been seen to increase with age. For example, animal model studies [Bahar et al., 2006, Herndon et al., 2002] have reported increased cell-to-cell variation in gene expression with age and tissue specific decline of functions associated to stochastic events. Others have found genes associated with longevity to be strongly regulated in older animals with low levels of stochasticity and higher levels of heritability [McCarroll et al., 2004, Viñuela et al., 2012]. The aim of our analysis was to find mean effects, rather than variance effects (though both effects are often seen together). By




FIGURE 1. Q-Q plot of observed p values against theoretical p values for factor analysis (red dots) and single-gene based methods (in blue). Permutations (in green) shows the results of a combined analysis of 10 permuted datasets. Horizontal lines show Bonferroni significance thresholds accounting for different numbers of tests (186 tests for single gene measures in blue, 930 for factor analysis in red, and 9300 for the combined 10 permutation analyses in green).

reducing the unique environment variable component using pathway factor analysis methods, we arguably focus much more on systematic longevity changes with age rather than the environmental stochasticity. However, it is difficult to make inference about causality

with gene expression: we cannot know whether we are observing changes in expression which are driving the ageing process, or markers for it. Previous studies have suggested that the latter may be the case, as often changes in gene expression occur in response to ageing [de Magalhaes et al., 2009].

Of the 57 significant pathways, we frequently see four types of pathway, all of which have been previously linked with ageing: i) insulin signalling ; ii) sugar and fatty acid metabolism; iii) xenobiotic metabolism; and iv) cancer related pathways.

We find the insulin signalling pathway (hsa04910) to be highly associated with age in our data ($P = 3.7 \times 10^{-10}$). Much evidence has accumulated for the influence of the insulin signalling pathway on longevity, originating in *C. elegans*, where lowered insulin/IGF-1 signalling (IIS) can lead to a significant increase in life span [Friedman and Johnson, 1988]. This effect has also been seen in the fruit fly *D. melanogaster* [Clancy et al., 2001] and in mice [Holzenberger et al., 2003]. Outside of model organisms, it has been observed that variants in FOXO transcription factors related to this pathway can affect longevity in humans [Willcox et al., 2008].

In addition to those related to insulin, our list of age-associated pathways includes many that are involved in metabolism or glycolysis. Examples of these include biosynthesis of unsaturated fatty acids (hsa00980), butanoate metabolism (hsa00650), glycolysis gluconeogenesis (hsa00010), fructose and mannose metabolism (hsa00051) and valine leucine and isoleucine biosynthesis (hsa00290). It has previously been suggested that metabolism related pathways play roles in ageing and ageing related diseases [Barzilai et al., 2012]. In particular, Houtkooper et al. [2011] showed that glucose and compounds involved in the metabolism of glucose were biomarkers of ageing in liver and muscle tissue in mice.

Other ageing related pathways include those involved in the metabolism of xenobiotics that allow cells to deactivate and excrete unexpected compounds. One example is glutathione metabolism (hsa00480, $P = 1.45 \times 10^{-7}$); glutathione is a well known anti-oxidant which protects against cell damage by reactive oxygen species [Pompella et al., 2003].

Finally, previous studies have shown that cancer risk is positively associated with age after childhood [Finkel et al., 2007, de Magalhães, 2013]. For example, cellular senescence, when a cell loses the ability to divide, can form a break on cancer development, and clearing such senescent cells can delay the development of age-associated disorders [Baker et al., 2011]. There are a number of pathways in our list that have been linked to cancer, in particular skin cancer. These include melanogenesis (hsa04916, $P = 3.34 \times 10^{-10}$), the

PPAR signalling pathway (hsa03320, $P = 1.83 \times 10^{-9}$), the hedgehog signalling pathway (hsa04340, $P = 1.12 \times 10^{-7}$) and glioma (hsa05214, $P = 4.26 \times 10^{-7}$)

In addition to age, other phenotypes have been linked to expression patterns of multiple genes. For example, BMI has been linked to expression patterns in adipose tissue of multiple genes within a group which share a common *trans* master regulator, and such phenotypes could mediate between expression and diseases such as type 2 diabetes [Small et al., 2011]. Principal components and factor analysis have also been suggested as a way to build classifiers for binary traits [Hastie et al., 2000], perhaps to predict prognosis of disease from gene expression data. The ability of pathway phenotypes to provide reliable measures of expression with direct biological interpretation means they could also be applied in these situations, to understand the relationship between expression and such phenotypes.

Our analysis shows that factor analysis applied to gene expression data effectively reduces stochastic noise in summaries of gene expression patterns, giving more power to discover associations. These phenotypes are substantially more heritable than individual genes. Using them we can improve our ability to identify biological processes underpinning ageing. This is consistent with the idea that removing latent factors that exert broad effects on gene expressions increases power in associations. We show that the same idea can be used to create pathway factors that are robust and interpretable. Finally, our analysis reveals pathways that have been seen to be important in longevity from a number of previous studies, as well as novel pathways that can be further investigated.

5. ACKNOWLEDGEMENT

We thank Silvia Chiappa and David A. Knowles for helpful discussions regarding the models. We thank the twins for their voluntary contribution to this project. Andrew Brown and Ana Viñuela are supported by the EU FP7 grant EuroBATS (No. 259749). In addition, Andrew Brown is supported by a grant from the South-Eastern Norway Health Authority, (No. 2011060). Richard Durbin is supported by Wellcome Trust grant WT098051. The data are derived from samples from the TwinsUK cohort, which is funded by the Wellcome Trust and the European Community's Seventh Framework Programme (FP7/2007-2013). TwinsUK also receives support from the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's and St Thomas' NHS Foundation

Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. Tim Spector is an NIHR Senior Investigator and is holder of an ERC Advanced Principal Investigator award.

REFERENCES

- R. Bahar, C.H. Hartmann, K.A. Rodriguez, A.D. Denny, R.A. Busuttil, M.E.T. Dollé, R.B. Calder, G.B. Chisholm, B.H. Pollock, C.A. Klein, et al. Increased cell-to-cell variation in gene expression in ageing mouse heart. *Nature*, 441(7096):1011–1014, 2006.
- D.J. Baker, T. Wijshake, T. Tchkonja, N.K. LeBrasseur, B.G. Childs, B. van de Sluis, J.L. Kirkland, and J.M. van Deursen. Clearance of p16^{Ink4a}-positive senescent cells delays ageing-associated disorders. *Nature*, 2011.
- Nir Barzilai, Derek M Huffman, Radhika H Muzumdar, and Andrzej Bartke. The critical role of metabolic pathways in aging. *Diabetes*, 61(6):1315–1322, 2012.
- Douglas Bates, Martin Maechler, Ben Bolker, and Steven Walker. *lme4: Linear mixed-effects models using Eigen and S4*, 2014. URL <http://CRAN.R-project.org/package=lme4>. R package version 1.0-6.
- D.J. Clancy, D. Gems, L.G. Harshman, S. Oldham, H. Stocker, E. Hafen, S.J. Leevers, and L. Partridge. Extension of life-span by loss of CHICO, a *Drosophila* insulin receptor substrate protein. *Science Signalling*, 292(5514):104, 2001.
- J. P. de Magalhaes, J. Curado, and G. M. Church. Meta-analysis of age-related gene expression profiles identifies common signatures of aging. *Bioinformatics*, 25(7):875–881, Apr 2009.
- João Pedro de Magalhães. How ageing processes influence cancer. *Nat Rev Cancer*, 13(5):357–65, May 2013. doi: 10.1038/nrc3497.
- T. Finkel, M. Serrano, and M.A. Blasco. The common biology of cancer and ageing. *Nature*, 448(7155):767–774, 2007.
- D.B. Friedman and T.E. Johnson. Three mutants that extend both mean and maximum life span of the nematode, *Caenorhabditis elegans*, define the age-1 gene. *Journal of Gerontology*, 43(4):B102–B109, 1988.
- D. Glass, A. Viñuela, M.N. Davies, A. Ramasamy, L. Parts, D. Knowles, A.A. Brown, Å.K. Hedman, K.S. Small1, A. Buil, E. Grundberg, A.C. Nica, P. Di Meglio, F.O. Nestle, M. Ryten, the UK Brain Expression Consortium, the MuTHER consortium, R. Durbin, M.I. McCarthy, P. Deloukas, E.T. Dermitzakis, M.E. Weale, V. Bataille,

- and T.D. Spector. Gene expression changes with age in skin, adipose, blood and brain. *Genome Biology*, 2013.
- E. Grundberg, K.S. Small, Å.K. Hedman, A.C. Nica, A. Buil, S. Keildson, J.T. Bell, T.P. Yang, E. Meduri, A. Barrett, et al. Mapping cis-and trans-regulatory effects across multiple tissues in twins. *Nature Genetics*, 44(10):1084–1089, 2012.
- T. Hastie, R. Tibshirani, M.B. Eisen, A. Alizadeh, R. Levy, L. Staudt, W.C. Chan, D. Botstein, P. Brown, et al. ‘Gene shaving’ as a method for identifying distinct sets of genes with similar expression patterns. *Genome Biology*, 1(2):1–0003, 2000.
- L.A. Herndon, P.J. Schmeissner, J.M. Dudaronek, P.A. Brown, K.M. Listner, Y. Sakano, M.C. Paupard, D.H. Hall, and M. Driscoll. Stochastic and genetic factors influence tissue-specific decline in ageing *C. elegans*. *Nature*, 419(6909):808–814, 2002.
- M. Holzenberger, J. Dupont, B. Ducos, P. Leneuve, A. Gélœn, P.C. Even, P. Cervera, Y. Le Bouc, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature*, 421(6919):182–187, 2003.
- Riekelt H Houtkooper, Carmen Argmann, Sander M Houten, Carles Cantó, Ellen H Jenninga, Pénélope A Andreux, Charles Thomas, Raphaël Doenlen, Kristina Schoonjans, and Johan Auwerx. The metabolic footprint of aging in mice. *Scientific Reports*, 1, 2011.
- Da Wei Huang, Brad T Sherman, and Richard A Lempicki. Systematic and integrative analysis of large gene lists using david bioinformatics resources. *Nat Protoc*, 4(1):44–57, 2009. doi: 10.1038/nprot.2008.211.
- Minoru Kanehisa, Susumu Goto, Shuichi Kawashima, Yasushi Okuno, and Masahiro Hattori. The kegg resource for deciphering the genome. *Nucleic Acids Research*, 32(suppl 1):D277–D280, 2004.
- Jeffrey T Leek and John D Storey. Capturing heterogeneity in gene expression studies by surrogate variable analysis. *PLoS Genetics*, 3(9):e161, 2007.
- Heng Li, Jue Ruan, and Richard Durbin. Mapping short dna sequencing reads and calling variants using mapping quality scores. *Genome Res*, 18(11):1851–8, Nov 2008. doi: 10.1101/gr.078212.108.
- T. Lu, Y. Pan, S.Y. Kao, C. Li, I. Kohane, J. Chan, and B.A. Yankner. Gene regulation and DNA damage in the ageing human brain. *Nature*, 429(6994):883–891, 2004.

- Steven A McCarroll, Coleen T Murphy, Sige Zou, Scott D Pletcher, Chen-Shan Chin, Yuh Nung Jan, Cynthia Kenyon, Cornelia I Bargmann, and Hao Li. Comparing genomic expression patterns across species identifies shared transcriptional profile in aging. *Nature Genetics*, 36(2):197–204, 2004.
- A. Moayyeri, C.J. Hammond, A.M. Valdes, and T.D. Spector. Cohort Profile: TwinsUK and Healthy Ageing Twin Study. *International Journal of Epidemiology*, 2012.
- Alexandra C Nica, Leopold Parts, Daniel Glass, James Nisbet, Amy Barrett, Magdalena Sekowska, Mary Travers, Simon Potter, Elin Grundberg, Kerrin Small, et al. The architecture of gene regulatory variation across multiple human tissues: the muther study. *PLoS genetics*, 7(2):e1002003, 2011.
- L. Parts, O. Stegle, J. Winn, and R. Durbin. Joint genetic analysis of gene expression data with inferred cellular phenotypes. *PLoS Genetics*, 7(1):e1001276, 2011.
- J. K. Pickrell, J. C. Marioni, A. A. Pai, J. F. Degner, B. E. Engelhardt, E. Nkadori, J. B. Veyrieras, M. Stephens, Y. Gilad, and J. K. Pritchard. Understanding mechanisms underlying human gene expression variation with RNA sequencing. *Nature*, 464(7289):768–772, Apr 2010.
- A. Pompella, A. Visvikis, A. Paolicchi, V.D. Tata, and A.F. Casini. The changing faces of glutathione, a cellular protagonist. *Biochemical Pharmacology*, 66(8):1499–1503, 2003.
- R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2013. URL <http://www.R-project.org>.
- Kerrin S Small, Åsa K Hedman, Elin Grundberg, Alexandra C Nica, Gudmar Thorleifsson, Augustine Kong, Unnur Thorsteindottir, So-Youn Shin, Hannah B Richards, et al. Identification of an imprinted master trans-regulator at the *klf14* locus related to multiple metabolic phenotypes. *Nature Genetics*, 43(6):561, 2011.
- O. Stegle, L. Parts, M. Piipari, J. Winn, and R. Durbin. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. *Nature Protocols*, 7(3):500–507, Mar 2012.
- Ana Viñuela, L Basten Snoek, Joost AG Riksen, and Jan E Kammenga. Aging uncouples heritability and expression-qt1 in *caenorhabditis elegans*. *G3: Genes—Genomes—Genetics*, 2(5):597–605, 2012.
- B.J. Willcox, T.A. Donlon, Q. He, R. Chen, J.S. Grove, K. Yano, K.H. Masaki, D.C. Willcox, B. Rodriguez, and J.D. Curb. FOXO3A genotype is strongly associated with

human longevity. *Proceedings of the National Academy of Sciences*, 105(37):13987–13992, 2008.

| KEGG_ID | Pathway | P value of pathway factor | Number of genes in pathway | Number of age associated genes | Heritability |
|---------|--|-----------------------------|----------------------------|--------------------------------|--------------|
| 00900 | Terpenoid Backbone Biosynthesis | 6.23×10^{-13} | 13 | 6 | 0.00 |
| 00980 | Metabolism of Xenobiotics by Cytochrome P450 | 6.47×10^{-13} | 54 | 6 | 0.09 |
| 01040 | Biosynthesis of Unsaturated Fatty Acids | 1.11×10^{-12} | 17 | 6 | 0.25 |
| 00100 | Steroid Biosynthesis | 1.33×10^{-12} | 14 | 12 | 0.41 |
| 00650 | Butanoate Metabolism | 1.51×10^{-12} | 27 | 8 | 0.39 |
| 04146 | Peroxisome | 1.56×10^{-12} | 64 | 17 | 0.45 |
| 00830 | Retinol Metabolism | 1.93×10^{-12} | 48 | 6 | 0.45 |
| 00010 | Glycolysis Gluconeogenesis | 3.59×10^{-12} | 49 | 12 | 0.42 |
| 00051 | Fructose and Mannose Metabolism | 3.99×10^{-12} | 32 | 8 | 0.32 |
| 00290 | Valine Leucine and Isoleucine Biosynthesis | 1.15×10^{-11} | 11 | 3 | 0.00 |
| 00561 | Glycerolipid Metabolism | 2.63×10^{-11} | 38 | 6 | 0.34 |
| 00620 | Pyruvate Metabolism | 4.20×10^{-11} | 35 | 11 | 0.37 |
| 00770 | Pantothenate and COA Biosynthesis | 4.76×10^{-11} | 16 | 4 | 0.48 |
| 00280 | Valine Leucine and Isoleucine Degradation | 5.79×10^{-11} | 35 | 10 | 0.51 |
| 00020 | Citrate Cycle TCA Cycle | 1.12×10^{-10} | 23 | 8 | 0.43 |
| 04916 | Melanogenesis | 3.34×10^{-10} | 93 | 10 | 0.00 |
| 04910 | Insulin Signalling Pathway | 3.70×10^{-10} | 122 | 13 | 0.45 |
| 00565 | Ether Lipid Metabolism | 5.89×10^{-10} | 27 | 3 | 0.00 |
| 00350 | Tyrosine Metabolism | 9.44×10^{-10} | 32 | 4 | 0.34 |
| 00640 | Propanoate Metabolism | 1.03×10^{-9} | 26 | 6 | 0.59 |

TABLE 1. List of 20 pathways most significantly associated with age, together with the total number of genes in the pathway, the number of genes within pathways significantly associated with age ($P < 0.05$, corrected using Bonferroni for the total number of genes in the pathway), and the heritability of the pathway factor.




FIGURE 2. Histograms showing the proportion of environmental variation explained by age, heritability, and the proportion of variance explained by the unique environment for pathway factors and the individual gene measurements.




FIGURE 3. The relative importance of sources of variation to global, pathway and gene phenotypes. Measures of variation shown are the proportion of variance explained by unique environment, proportion of variance explained by genetics (heritability) and the proportion of environmental variation explained by age. To show more clearly the differences in relative importance of these measures to different classes of phenotypes, all proportions are scaled such that contribution to gene phenotypes equals one. Numbers above the bars give the absolute, unscaled proportions.

SUPPLEMENTARY MATERIALS

Table S1: List of all pathways significantly associated with age, together with the number of genes significantly associated with age ($p < 0.05$, corrected using Bonferroni for the total number of genes in the pathway) and the total number of genes in the pathway.

| KEGG ID | Pathway | P value | Number of age associated genes | Total number of genes |
|---------|---|------------------------|---|--------------------------|
| 00900 | Terpenoid Backbone Biosynthesis | 6.23×10^{-13} | 6 | 13 |
| 00980 | Metabolism of Xenobiotics By Cytochrome P450 | 6.47×10^{-13} | 6 | 54 |
| 01040 | Biosynthesis of Unsaturated Fatty Acids | 1.11×10^{-12} | 6 | 17 |
| 00100 | Steroid Biosynthesis | 1.33×10^{-12} | 12 | 14 |
| 00650 | Butanoate Metabolism | 1.51×10^{-12} | 8 | 27 |
| 04146 | Peroxisome | 1.56×10^{-12} | 17 | 64 |
| 00830 | Retinol Metabolism | 1.93×10^{-12} | 6 | 48 |
| 00010 | Glycolysis Gluconeogenesis | 3.59×10^{-12} | 12 | 49 |
| 00051 | Fructose and Mannose Metabolism | 3.99×10^{-12} | 8 | 32 |
| 00290 | Valine Leucine and Isoleucine Biosynthesis | 1.15×10^{-11} | 3 | 11 |
| 00561 | Glycerolipid Metabolism | 2.63×10^{-11} | 6 | 38 |
| 00620 | Pyruvate Metabolism | 4.2×10^{-11} | 11 | 35 |
| 00770 | Pantothenate and COA Biosynthesis | 4.76×10^{-11} | 4 | 16 |
| 00280 | Valine Leucine and Isoleucine Degradation | 5.79×10^{-11} | 10 | 35 |
| 00020 | Citrate Cycle TCA Cycle | 1.12×10^{-10} | 8 | 23 |
| 04916 | Melanogenesis | 3.34×10^{-10} | 10 | 93 |

Continued on next page

Table S1 – *Continued from previous page*

| KEGG ID | Pathway | <i>P</i> value | Age-associated genes | Total number of genes |
|---------|--|------------------------|----------------------|-----------------------|
| 04910 | Insulin Signalling Pathway | 3.7×10^{-10} | 13 | 122 |
| 00565 | Ether Lipid Metabolism | 5.89×10^{-10} | 3 | 27 |
| 00350 | Tyrosine Metabolism | 9.44×10^{-10} | 4 | 32 |
| 00640 | Propanoate Metabolism | 1.03×10^{-9} | 6 | 26 |
| 04530 | Tight Junction | 1.12×10^{-9} | 11 | 106 |
| 00030 | Pentose Phosphate Pathway | 1.74×10^{-9} | 8 | 21 |
| 03320 | PPAR Signalling Pathway | 1.83×10^{-9} | 10 | 56 |
| 00630 | Glyoxylate and Dicarboxylate Metabolism | 2.22×10^{-9} | 4 | 11 |
| 00982 | Drug Metabolism Cytochrome P450 | 2.93×10^{-9} | 6 | 55 |
| 00260 | Glycine Serine and Threonine Metabolism | 7.02×10^{-9} | 4 | 30 |
| 00140 | Steroid Hormone Biosynthesis | 7.49×10^{-9} | 7 | 44 |
| 00380 | Tryptophan Metabolism | 1.17×10^{-8} | 6 | 32 |
| 04930 | Type II Diabetes Mellitus | 1.98×10^{-8} | 5 | 44 |
| 05412 | Arrhythmogenic Right Ventricular Cardiomyopathy Arvc | 7.44×10^{-8} | 7 | 70 |
| 00052 | Galactose Metabolism | 9.27×10^{-8} | 3 | 24 |
| 04340 | Hedgehog Signaling Pathway | 1.12×10^{-7} | 7 | 52 |
| 00480 | Glutathione Metabolism | 1.45×10^{-7} | 7 | 39 |
| 00532 | Glycosaminoglycan Biosynthesis Chondroitin Sulfate | 1.53×10^{-7} | 5 | 16 |
| 04920 | Adipocytokine Signaling Pathway | 2.87×10^{-7} | 9 | 61 |
| 05214 | Glioma | 4.26×10^{-7} | 6 | 59 |
| 05322 | Systemic Lupus Erythematosus | 4.56×10^{-7} | 7 | 87 |
| 05414 | Dilated Cardiomyopathy | 5.64×10^{-7} | 6 | 84 |

Continued on next page

Table S1 – *Continued from previous page*

| KEGG ID | Pathway | <i>P</i> value | Age-associated genes | Total number of genes |
|---------|--|-----------------------|----------------------|-----------------------|
| 00410 | Beta Alanine Metabolism | 1.11×10^{-6} | 4 | 19 |
| 00330 | Arginine and Proline Metabolism | 1.39×10^{-6} | 11 | 47 |
| 04510 | Focal Adhesion | 1.47×10^{-6} | 18 | 173 |
| 00340 | Histidine Metabolism | 1.53×10^{-6} | 3 | 25 |
| 04360 | Axon Guidance | 1.66×10^{-6} | 15 | 119 |
| 04060 | ECM Receptor Interaction | 1.77×10^{-6} | 13 | 71 |
| 04150 | MTOR Signaling Pathway | 2.02×10^{-6} | 3 | 43 |
| 04270 | Vascular Smooth Muscle Contraction | 3.31×10^{-6} | 14 | 103 |
| 00071 | Fatty Acid Metabolism | 3.84×10^{-6} | 8 | 30 |
| 04142 | Lysosome | 4.43×10^{-6} | 14 | 106 |
| 00983 | Drug Metabolism Other Enzymes | 5.71×10^{-6} | 4 | 43 |
| 00040 | Pentose and Glucuronate Interconversions | 6.49×10^{-6} | 1 | 21 |
| 05416 | Viral Myocarditis | 1.16×10^{-5} | 5 | 51 |
| 00520 | Amino Sugar and Nucleotide Sugar Metabolism | 1.7×10^{-5} | 7 | 39 |
| 05217 | Basal Cell Carcinoma | 1.8×10^{-5} | 10 | 52 |
| 00510 | N-Glycan Biosynthesis | 1.82×10^{-5} | 7 | 40 |
| 04260 | Cardiac Muscle Contraction | 1.83×10^{-5} | 5 | 59 |
| 05216 | Thyroid Cancer | 1.99×10^{-5} | 8 | 60 |
| 05120 | Epithelial Cell Signaling in Helicobacter Pylori Infection | 4.85×10^{-5} | 11 | 59 |

| KEGG ID | Pathway | <i>P</i> value |
|---------|--|------------------------|
| 00650 | Butanoate Metabolism | 8.86×10^{-6} |
| 04060 | ECM Receptor Interaction | 3.64×10^{-5} |
| 04146 | Peroxisome | 2.61×10^{-7} |
| 00620 | Pyruvate Metabolism | 5.49×10^{-5} |
| 00100 | Steroid Biosynthesis | 2.39×10^{-11} |
| 00900 | Terpenoid Backbone Biosynthesis | 2.13×10^{-5} |
| 00290 | Valine Leucine and Isoleucine Degradation | 5.58×10^{-6} |

TABLE S2. List of the seven pathways which were significantly associated with age, discovered by looking for enrichment of single gene age associations.




FIGURE S1. Network of connected factor phenotypes. Twenty four of the 69 age-associated factor phenotypes have a Spearman correlation of at least 0.8 with at least one other phenotype. These phenotypes show a highly connected structure, likely meaning there are common age effects driving these associations. A key for identifying which pathways correspond to the nodes can be found in Supplementary Table S3.

| Node | Pathway | Maximum ρ with other phenotype |
|------|--|-------------------------------------|
| 1 | Butanoate Metabolism | 0.94 |
| 2 | Valine Leucine and Isoleucine Degradation | 0.94 |
| 3 | Biosynthesis of Unsaturated Fatty Acids | 0.92 |
| 4 | Peroxisome | 0.92 |
| 5 | Propanoate Metabolism | 0.92 |
| 6 | Pyruvate Metabolism | 0.91 |
| 7 | Glycolysis Gluconeogenesis | 0.91 |
| 8 | Terpenoid Backbone Biosynthesis | 0.90 |
| 9 | Steroid Biosynthesis | 0.90 |
| 10 | Citrate Cycle TCA Cycle | 0.90 |
| 11 | Glycerolipid Metabolism | 0.90 |
| 12 | Retinol Metabolism | 0.90 |
| 13 | Fatty Acid Metabolism | 0.87 |
| 14 | Beta Alanine Metabolism | 0.85 |
| 15 | Glutathione Metabolism | 0.85 |
| 16 | Pantothenate and COA Biosynthesis | 0.85 |
| 17 | Drug Metabolism Cytochrome P450 | 0.84 |
| 18 | Insulin Signaling Pathway | 0.84 |
| 19 | Steroid Hormone Biosynthesis | 0.84 |
| 20 | Valine Leucine and Isoleucine Biosynthesis | 0.84 |
| 21 | Pentose Phosphate Pathway | 0.84 |
| 22 | Fructose and Mannose Metabolism | 0.84 |
| 23 | Tryptophan Metabolism | 0.82 |
| 24 | Glyoxylate and Dicarboxylate Metabolism | 0.80 |

TABLE S3. Key showing which pathways correspond to which nodes in Supplementary Figure S1, and the maximum Spearman correlation of that phenotype with any of the others representing pathways.

Table S4: Heritability and proportion of environmental variation explained by age for all pathways. Value reported is for the pathway phenotype most significantly associated with ageing.

| KEGG ID | Pathway | Heritability | Proportion (age) |
|---------|---|------------------------|---------------------|
| 00900 | Terpenoid Backbone Biosynthesis | 1.53×10^{-11} | 0.0898 |
| 00980 | Metabolism of Xenobiotics By Cytochrome P450 | 0.0904 | 0.0986 |
| 01040 | Biosynthesis of Unsaturated Fatty Acids | 0.253 | 0.11 |
| 00100 | Steroid Biosynthesis | 0.406 | 0.143 |
| 00650 | Butanoate Metabolism | 0.39 | 0.137 |
| 04146 | Peroxisome | 0.453 | 0.152 |
| 00830 | Retinol Metabolism | 0.449 | 0.149 |
| 00010 | Glycolysis Gluconeogenesis | 0.417 | 0.14 |
| 00051 | Fructose and Mannose Metabolism | 0.316 | 0.109 |
| 00290 | Valine Leucine and Isoleucine Biosynthesis | 2.61×10^{-12} | 0.0771 |
| 00561 | Glycerolipid Metabolism | 0.337 | 0.113 |
| 00620 | Pyruvate Metabolism | 0.368 | 0.117 |
| 00770 | Pantothenate and COA Biosynthesis | 0.477 | 0.136 |
| 00280 | Valine Leucine and Isoleucine Degradation | 0.51 | 0.147 |
| 00020 | Citrate Cycle TCA Cycle | 0.436 | 0.126 |
| 04916 | Melanogenesis | 2.23×10^{-16} | 0.0708 |
| 04910 | Insulin Signaling Pathway | 0.453 | 0.121 |
| 00565 | Ether Lipid Metabolism | 1.13×10^{-15} | 0.064 |
| 00350 | Tyrosine Metabolism | 0.342 | 0.0975 |
| 00640 | Propanoate Metabolism | 0.591 | 0.157 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|---|------------------------|------------|
| 04530 | Tight Junction | 0.103 | 0.0751 |
| 00030 | Pentose Phosphate Pathway | 0.291 | 0.0831 |
| 03320 | PPAR Signaling Pathway | 0.235 | 0.0777 |
| 00630 | Glyoxylate and Dicarboxylate Metabolism | 0.275 | 0.0836 |
| 00982 | Drug Metabolism Cytochrome P450 | 0.248 | 0.0811 |
| 00260 | Glycine Serine and Threonine Metabolism | 0.599 | 0.141 |
| 00140 | Steroid Hormone Biosynthesis | 0.655 | 0.167 |
| 00380 | Tryptophan Metabolism | 0 | 0.0491 |
| 04930 | Type II Diabetes Mellitus | 0.594 | 0.13 |
| 05412 | Arrhythmogenic Right Ventricular Cardiomyopathy Arvc | 0.241 | 0.0674 |
| 00052 | Galactose Metabolism | 3.4×10^{-11} | 0.0504 |
| 04340 | Hedgehog Signaling Pathway | 0.375 | 0.08 |
| 00480 | Glutathione Metabolism | 0.415 | 0.0804 |
| 00532 | Glycosaminoglycan Biosynthesis Chondroitin Sulfate | 0.273 | 0.0682 |
| 04920 | Adipocytokine Signaling Pathway | 1.3×10^{-20} | 0.0475 |
| 05214 | Glioma | 0.102 | 0.0466 |
| 05322 | Systemic Lupus Erythematosus | 8.17×10^{-17} | 0.045 |
| 05414 | Dilated Cardiomyopathy | 0.532 | 0.0867 |
| 00410 | Beta Alanine Metabolism | 0.709 | 0.14 |
| 00330 | Arginine and Proline Metabolism | 1.7×10^{-16} | 0.0402 |
| 04510 | Focal Adhesion | 0.397 | 0.0669 |
| 00340 | Histidine Metabolism | 0.519 | 0.0874 |
| 04360 | Axon Guidance | 0.606 | 0.0995 |
| 04060 | ECM Receptor Interaction | 0.792 | 0.196 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|---|------------------------|------------|
| 04150 | MTOR Signaling Pathway | 0.219 | 0.0511 |
| 04270 | Vascular Smooth Muscle Contraction | 0.27 | 0.0542 |
| 00071 | Fatty Acid Metabolism | 0.823 | 0.204 |
| 04142 | Lysosome | 0.566 | 0.0804 |
| 00983 | Drug Metabolism Other Enzymes | 0 | 0.0322 |
| 00040 | Pentose and Glucuronate Interconversions | 0.562 | 0.0792 |
| 05416 | Viral Myocarditis | 0.569 | 0.0815 |
| 00520 | Amino Sugar and Nucleotide Sugar Metabolism | 0.453 | 0.0577 |
| 05217 | Basal Cell Carcinoma | 0.593 | 0.0799 |
| 00510 | N Glycan Biosynthesis | 5.87×10^{-16} | 0.0313 |
| 04260 | Cardiac Muscle Contraction | 8.3×10^{-13} | 0.0312 |
| 05216 | Thyroid Cancer | 2.56×10^{-9} | 0.0332 |
| 05120 | Epithelial Cell Signaling in Helicobacter Pylori Infection | 0.652 | 0.0859 |
| 04060 | Cytokine Cytokine Receptor Interaction | 3.51×10^{-17} | 0.0276 |
| 00120 | Primary Bile Acid Biosynthesis | 1.69×10^{-16} | 0.0265 |
| 00190 | Oxidative Phosphorylation | 1.41×10^{-11} | 0.0268 |
| 00760 | Nicotinate and Nicotinamide Metabolism | 0.401 | 0.0433 |
| 00360 | Phenylalanine Metabolism | 0.711 | 0.088 |
| 00512 | O Glycan Biosynthesis | 1.78×10^{-18} | 0.0253 |
| 05213 | Endometrial Cancer | 0.428 | 0.0408 |
| 00250 | Alanine Aspartate and Glutamate Metabolism | 0.526 | 0.0507 |
| 00564 | Glycerophospholipid Metabolism | 0 | 0.0231 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|--|------------------------|------------|
| 04012 | ERBB Signaling Pathway | 0.121 | 0.0253 |
| 05211 | Renal Cell Carcinoma | 3.64×10^{-11} | 0.0237 |
| 02010 | ABC Transporters | 0.506 | 0.0454 |
| 04710 | Circadian Rhythm Mammal | 0.0407 | 0.0292 |
| 05222 | Small Cell Lung Cancer | 1.03×10^{-17} | 0.024 |
| 04062 | Chemokine Signaling Pathway | 0.124 | 0.0277 |
| 00590 | Arachidonic Acid Metabolism | 0.141 | 0.027 |
| 04610 | Complement and Coagulation Cascades | 0.504 | 0.0453 |
| 03022 | Basal Transcription Factors | 0.537 | 0.0424 |
| 00600 | Sphingolipid Metabolism | 8.68×10^{-19} | 0.0219 |
| 05410 | Hypertrophic Cardiomyopathy Hcm | 3.3×10^{-13} | 0.0147 |
| 04912 | GNRH Signaling Pathway | 3.11×10^{-16} | 0.0187 |
| 04720 | Long Term Potentiation | 0 | 0.0183 |
| 03050 | Proteasome | 0.425 | 0.0314 |
| 04620 | JAK Stat Signaling Pathway | 0.503 | 0.0382 |
| 05330 | Allograft Rejection | 0 | 0.016 |
| 03450 | Non Homologous End Joining | 0.132 | 0.0199 |
| 05320 | Autoimmune Thyroid Disease | 0 | 0.0156 |
| 03060 | Protein Export | 0.235 | 0.0197 |
| 03420 | Nucleotide Excision Repair | 3.19×10^{-14} | 0.0178 |
| 00660 | Alpha Linolenic Acid Metabolism | 0.458 | 0.0311 |
| 04144 | Endocytosis | 0.0714 | 0.0181 |
| 05010 | Alzheimers Disease | 0.0757 | 0.0172 |
| 00591 | Linoleic Acid Metabolism | 3×10^{-11} | 0.0159 |
| 00240 | Pyrimidine Metabolism | 6.42×10^{-13} | 0.0152 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|--|------------------------|------------|
| 00270 | Cysteine and Methionine Metabolism | 0.00281 | 0.0162 |
| 03410 | Base Excision Repair | 0.377 | 0.0219 |
| 04722 | Neurotrophin Signaling Pathway | 4.88×10^{-18} | 0.0152 |
| 04070 | Phosphatidylinositol Signaling System | 0.312 | 0.0207 |
| 04960 | Aldosterone Regulated Sodium Reabsorption | 3.36×10^{-15} | 0.0142 |
| 05130 | Pathogenic Escherichia Coli Infection | 0.158 | 0.0158 |
| 04310 | WNT Signaling Pathway | 0.176 | 0.0174 |
| 00562 | Inositol Phosphate Metabolism | 3.24×10^{-16} | 0.0138 |
| 05221 | Acute Myeloid Leukemia | 0.472 | 0.0268 |
| 00071 | Selenoamino Acid Metabolism | 3.71×10^{-10} | 0.0137 |
| 04742 | Taste Transduction | 0.149 | 0.0174 |
| 00531 | Glycosaminoglycan Degradation | 2.23×10^{-19} | 0.0135 |
| 05340 | Primary Immunodeficiency | 0 | 0.0133 |
| 04640 | Hematopoietic Cell Lineage | 2.35×10^{-16} | 0.0132 |
| 05310 | Asthma | 0.331 | 0.0183 |
| 04620 | TGF Beta Signaling Pathway | 1.72×10^{-18} | 0.0131 |
| 00860 | Porphyrin and Chlorophyll Metabolism | 9.84×10^{-16} | 0.0124 |
| 04612 | Antigen Processing and Presentation | 2.03×10^{-11} | 0.0129 |
| 05010 | Parkinsons Disease | 4.25×10^{-9} | 0.012 |
| 00790 | Folate Biosynthesis | 1.07×10^{-11} | 0.0119 |
| 00500 | Starch and Sucrose Metabolism | 0.429 | 0.0111 |
| 05223 | Non Small Cell Lung Cancer | 0 | 0.0115 |
| 03030 | DNA Replication | 0 | 0.0116 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|--|------------------------|------------|
| 04622 | RIG I Like Receptor Signaling Pathway | 0 | 0.0117 |
| 04666 | FC Gamma R Mediated Phagocytosis | 0.747 | 0.0415 |
| 04514 | Cell Adhesion Molecules CAMS | 0.278 | 0.016 |
| 03430 | Mismatch Repair | 7.18×10^{-17} | 0.011 |
| 03010 | Ribosome | 8.63×10^{-19} | 0.0108 |
| 05220 | Chronic Myeloid Leukemia | 0.333 | 0.0164 |
| 00910 | Nitrogen Metabolism | 0 | 0.0106 |
| 04330 | Notch Signaling Pathway | 0.585 | 0.0251 |
| 04520 | Adherens Junction | 1.15×10^{-9} | 0.0107 |
| 05210 | Colorectal Cancer | 0.289 | 0.0141 |
| 03018 | RNA Degradation | 1.03×10^{-13} | 0.00998 |
| 03440 | Homologous Recombination | 0 | 0.0093 |
| 00920 | Sulfur Metabolism | 0.121 | 0.011 |
| 00310 | Lysine Degradation | 0.446 | 0.0166 |
| 04662 | B Cell Receptor Signaling Pathway | 0.494 | 0.0183 |
| 00430 | Taurine and Hypotaurine Metabolism | 8.53×10^{-13} | 0.00891 |
| 04964 | Proximal Tubule Bicarbonate Reclamation | 0.456 | 0.0163 |
| 04614 | Renin Angiotensin System | 0.556 | 0.0183 |
| 00970 | Aminoacyl tRNA Biosynthesis | 0.107 | 0.0102 |
| 04672 | Intestinal Immune Network For IGA Production | 0 | 0.00883 |
| 04810 | Regulation of Actin Cytoskeleton | 0.215 | 0.0104 |
| 05215 | Prostate Cancer | 1.55×10^{-9} | 0.00719 |
| 00563 | Glycosylphosphatidylinositol Gpi Anchor Biosynthesis | 0 | 0.00816 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|--|------------------------|------------|
| 04660 | NOD Like Receptor Signaling Pathway | 0 | 0.00828 |
| 04540 | Gap Junction | 0.121 | 0.0096 |
| 00903 | Limonene and Pinene Degradation | 4.8×10^{-12} | 0.00822 |
| 05200 | Pathways in Cancer | 0.275 | 0.0119 |
| 04660 | Toll Like Receptor Signaling Pathway | 8.13×10^{-17} | 0.00782 |
| 04730 | Long Term Depression | 0.128 | 0.00885 |
| 04020 | Calcium Signaling Pathway | 0.148 | 0.00936 |
| 04320 | Dorso Ventral Axis Formation | 0.271 | 0.00857 |
| 05110 | Vibrio Cholerae Infection | 0.353 | 0.011 |
| 04115 | P53 Signaling Pathway | 1.07 | -0.0975 |
| 04962 | Vasopressin Regulated Water Reabsorption | 0.331 | 0.0107 |
| 04670 | Leukocyte Transendothelial Migration | 0.248 | 0.00871 |
| 03020 | RNA Polymerase | 2.52×10^{-16} | 0.00609 |
| 04664 | FC Epsilon RI Signaling Pathway | 0.35 | 0.00908 |
| 04140 | Regulation of Autophagy | 0 | 0.00509 |
| 05010 | Huntingtons Disease | 0.894 | 0.0529 |
| 00670 | One Carbon Pool By Folate | 9.11×10^{-13} | 0.00564 |
| 04660 | T Cell Receptor Signaling Pathway | 0.487 | 0.0103 |
| 00740 | Riboflavin Metabolism | 0.252 | 0.00627 |
| 00533 | Glycosaminoglycan Biosynthesis Keratan Sulfate | 0 | 0.00452 |
| 00230 | Purine Metabolism | 3.84×10^{-18} | 0.00462 |
| 04130 | Snare Interactions in Vesicular Transport | 1.2×10^{-17} | 0.00475 |
| 05020 | Prion Diseases | 0.272 | 0.0059 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|---|------------------------|------------|
| 05219 | Bladder Cancer | 0.229 | 0.00531 |
| 03040 | Spliceosome | 0.224 | 0.00573 |
| 04010 | Mapk Signaling Pathway | 0.221 | 0.00506 |
| 00534 | Glycosaminoglycan Biosynthesis Heparan Sulfate | 1.4×10^{-18} | 0.00416 |
| 00604 | Glycosphingolipid Biosynthesis Ganglio Series | 0 | 0.00372 |
| 04940 | Type I Diabetes Mellitus | 0.446 | 0.00735 |
| 04623 | Cytosolic DNA Sensing Pathway | 0.431 | 0.00706 |
| 05332 | Graft Versus Host Disease | 0.432 | 0.00691 |
| 04740 | Olfactory Transduction | 0 | 0.0035 |
| 04110 | Cell Cycle | 5.02×10^{-18} | 0.00369 |
| 00511 | Other Glycan Degradation | 1.07×10^{-24} | 0.00321 |
| 05140 | Leishmania Infection | 0.136 | 0.00381 |
| 04914 | Progesterone Mediated Oocyte Maturation | 1.82×10^{-19} | 0.00322 |
| 04120 | Ubiquitin Mediated Proteolysis | 2.55×10^{-15} | 0.00315 |
| 00604 | Glycosphingolipid Biosynthesis Globo Series | 0 | 0.00271 |
| 00601 | Glycosphingolipid Biosynthesis Lacto and Neolacto Series | 0.213 | 0.00341 |
| 04370 | VEGF Signaling Pathway | 0.192 | 0.00362 |
| 00053 | Ascorbate and Aldarate Metabolism | 0 | 0.00197 |
| 04650 | Natural Killer Cell Mediated Cytotoxicity | 4.16×10^{-19} | 0.00222 |
| 05212 | Pancreatic Cancer | 5.99×10^{-48} | 0.00212 |
| 04114 | Oocyte Meiosis | 1.82×10^{-11} | 0.00201 |
| 04210 | Apoptosis | 0.632 | 0.00523 |

Continued on next page

Table S4 – *Continued from previous page*

| KEGG ID | Pathway | Heritability | Proportion |
|---------|--|------------------------|------------|
| 05218 | Melanoma | 0.349 | 0.00284 |
| 04080 | Neuroactive Ligand Receptor Interaction | 1.76×10^{-17} | 0.00158 |
| 05014 | Amyotrophic Lateral Sclerosis ALS | 0 | 0.00102 |
| 04950 | Maturity Onset Diabetes of The Young | 8.21×10^{-12} | 0.000707 |